-
MLN4924 HCl Salt: NAE Research Workflows
2026-08-20
MLN4924 HCl salt gives researchers a temporally controllable way to interrogate NAE-dependent cullin-RING ligase activity, protein turnover, cell-cycle control, and inflammatory cell death. This workflow connects pathway validation in cancer biology research with a reference-supported strategy for testing how viral proteins exploit host ubiquitination machinery.
-
Valemetostat and Dual EZH1/2 Inhibition in ATL
2026-08-19
The reference paper examines valemetostat, the first approved dual EZH1/2 inhibitor, and explains why simultaneous blockade of both PRC2 catalytic subunits is relevant to adult T-cell leukemia/lymphoma. Its clinical synthesis links the epigenetic mechanism to responses in relapsed or refractory disease while highlighting the need for larger controlled studies.
-
Recombinant Human FGF-19 Workflow Guide
2026-08-19
Build reproducible FGFR4 binding, proliferation, and metabolic signaling assays with a tag-free, lyophilized FGF-19 protein. This guide also shows how to use the sepsis-AKI WIP1/p38 MAPK study as a disciplined framework for exploratory cross-pathway experiments without overstating the evidence.
-
RIPA Lysis Buffer (Strong) for BBB Protein Studies
2026-08-18
RIPA Lysis Buffer (Strong) supports scalable protein extraction from brain tissues, astrocytes, and endothelial cultures for Western blotting, ELISA, and pathway-focused assays. Its strong detergent system improves recovery from difficult samples, while inhibitor supplementation and controlled handling help preserve inflammatory and tight-junction targets.
-
Puromycin Dihydrochloride: Practical Workflows
2026-08-18
Puromycin dihydrochloride combines fast, mechanism-defined selection with flexible perturbation of protein synthesis and ribosome behavior. This guide translates those properties into kill-curve, stable-line, translation-assay, and bladder cancer model workflows while separating established practice from exploratory applications.
-
MEG3, TGF-β, and NiO Nanoparticle Fibrosis
2026-08-17
The reference study identifies lncRNA MEG3 as a protective regulator in nickel oxide nanoparticle-induced pulmonary fibrosis, linking MEG3 suppression to TGF-β1-dependent PI3K/AKT activation and collagen deposition. Its combined rat, A549-cell, inhibitor, and MEG3-overexpression experiments provide a mechanistic framework for studying nanomaterial-induced lung injury, while also defining important limits for translation.
-
Nanoparticle Uptake in Human Corneal Epithelium
2026-08-17
Azadi and David systematically examined how PLGA nanoparticle size and surface chemistry influence uptake by human cornea epithelial cells. Their in vitro model links particle design to endocytic mechanisms, identifying macropinocytosis and caveolae-mediated endocytosis as dominant pathways and highlighting 100 nm PLGA and PEG-PLGA-150 particles as strong uptake candidates.
-
5X Protein Loading Buffer (Reducing) Guide
2026-08-16
5X Protein Loading Buffer (Reducing) prepares protein samples for conventional SDS-PAGE by combining SDS-mediated denaturation with disulfide-bond reduction and tracking-dye visualization. It is intended for reducing, denaturing workflows and should not be used when native conformation or non-reducing protein structure must be preserved.
-
GSK2606414 in PERK-Driven Metabolic Stress
2026-08-15
GSK2606414 is a potent PERK inhibitor for dissecting how ER stress becomes metabolic liver injury. This article translates recent TMAO–NAFLD findings into a causal assay strategy while defining controls, readouts, and interpretation limits.
-
4-Phenylbutyric acid in ER-Stress Assays
2026-08-14
Discover how 4-Phenylbutyric acid and 4-PBA can transform PFOS kidney-toxicity studies from descriptive ER-stress assays into causal experiments. This guide connects chemical-chaperone biology, ferroptosis readouts, and reproducible HK-2 cell assay design.
-
SR 11302 AP-1 Inhibitor: Assay Guide
2026-08-14
A scenario-based guide to using SR 11302 (AP-1 transcription factor inhibitor), SKU A8185, in cell proliferation, viability, cytotoxicity, and pathway-interrogation workflows. It connects product handling details with cancer and macrophage research evidence to improve experimental interpretation and vendor selection.
-
Phosphatase Inhibitor Cocktail 3 in Ferroptosis
2026-08-13
Phosphatase Inhibitor Cocktail 3 helps preserve labile phosphorylation states while investigating ferroptosis, mitochondrial permeability transition, and cGAS–STING signaling. This guide translates a recent oxidized mtDNA study into practical decisions for lysate preparation, phosphoprotein analysis, and orthogonal assay validation.
-
ZCL278: A Translational Cdc42 Strategy
2026-08-13
ZCL278 provides a selective small-molecule approach to interrogating Cdc42-dependent motility, neuronal morphogenesis, and disease-relevant signaling. This thought-leadership analysis connects its cellular evidence with Cdc42-mediated GSK-3β/β-catenin signaling in kidney fibrosis while defining the controls needed for credible translational interpretation.
-
Silymarin: Silybin A Workflows for Liver Research
2026-08-12
Build more reproducible liver and cancer assays with defined Silybin A rather than relying only on complex botanical mixtures. This guide connects solubility-aware dosing, viability controls, migration assays, and pathway validation to practical hepatoprotection, oxidative stress, and fibrosis research.
-
Forsythoside E: PKM2 State and Assay Design
2026-08-12
Forsythoside E is a PKM2 inhibitor with a distinctive immunometabolic mechanism. This article connects macrophage glycolysis studies with podocyte-focused diabetic kidney disease assays, emphasizing state-aware readouts, translational boundaries, and practical protocol design.